Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 24

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 24
---
-derived castanospermine regimens may potentially beneficial metabolic and immunomodulatory effects. The development
and commercialization route for botanical extracts is far more efficient and less costly than for prescription pharmaceuticals.

<div align='center'>S-13</div>

Registered Direct Offerings

February 2025 Offering

On February 5, 2025, we entered into a securities
purchase agreement (the “February 2025 Securities Purchase Agreement”) with certain institutional investors (the “February
2025 Purchasers”) pursuant to which the Company sold, in a registered direct offering an aggregate of 300,700 shares (the “February
2025 Shares”) of common stock at a purchase price of $3.575 per share in a registered direct offering (the “February 2025
Offering”) priced at-the-market under the rules of The Nasdaq Stock Market LLC (“Nasdaq”). The February 2025 Offering
closed on February 6, 2025.

The February 2025 Shares were offered pursuant
to a “shelf” registration statement on Form S-3 (Registration No. 333-280796), which was declared effective by the SEC on
July 18, 2024 as supplemented by a prospectus supplement dated February 5, 2025, filed with the SEC on February 6, 2025 and accompanying
base prospectus, pursuant to Rule 424(b)(5) promulgated under the Securities Act.

In a concurrent private placement, the Company
also issued to the February 2025 Purchasers unregistered warrants (the “February 2025 Warrants”) to purchase up to an aggregate
of 300,700 shares of common stock at an exercise price of $2.95 per share, subject to certain adjustments. The February 2025 Warrants
are exercisable upon issuance and expire twenty-four months from the date of issuance.

The Company filed a registration statement (the
“Selling Shareholder S-1”) with the SEC that registered the February 2025 Shares and the shares underlying the February 2025
Warrants, which was declared effective by the SEC on April 2, 2025.

The issuance of the February 2025 Warrants pursuant
to the February 2025 Securities Purchase Agreement and issuance of the February 2025 Placement Agent Warrants (as defined below) were
made pursuant to the exemption from the registration requirements under the Securities Act, available to the Company under Section 4(a)(2